Cargando…
Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia
The standard-of-care treatment of T-cell acute lymphoblastic leukaemia (T-ALL) with chemotherapy usually achieves reasonable rates of initial complete response. However, patients who relapse or do not respond to conventional therapy show dismal outcomes, with cure rates below 10% and limited therape...
Autores principales: | Villa-Morales, María, Pérez-Gómez, Laura, Pérez-Gómez, Eduardo, López-Nieva, Pilar, Fernández-Navarro, Pablo, Santos, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299336/ https://www.ncbi.nlm.nih.gov/pubmed/37373496 http://dx.doi.org/10.3390/ijms241210350 |
Ejemplares similares
-
Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma
por: López-Nieva, Pilar, et al.
Publicado: (2019) -
RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas
por: López-Nieva, Pilar, et al.
Publicado: (2018) -
Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia
por: Moreira-Nunes, Caroline Aquino, et al.
Publicado: (2020) -
Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities
por: López Villar, Elena, et al.
Publicado: (2014) -
TYK2 Variants in B-Acute Lymphoblastic Leukaemia
por: Turrubiartes-Martínez, Edgar, et al.
Publicado: (2020)